Andrew Fein


Steadymed (STDY) Lands Price Target Boost from H.C. Wainwright Following Big Legal Sweep for Trevyent

There were cheers from Steadymed (NASDAQ:STDY) investors last Friday following The Patent Trial and Appeal Board’s (PTAB) favorable decision granted to the biotech firm …

H.C. Wainwright Dives In on Amarin Corporation plc (ADR) (AMRN) as REDUCE-IT Topline Data Within Sight

As REDUCE-IT continues to track to expected read-outs in early 2018, H.C.

H.C. Wainwright’s Take On Nivalis Therapeutics Inc (NVLS) Clinical Trial Setback

Nivalis Therapeutics Inc (NASDAQ:NVLS) investors are heading for the hills after the drug maker reported that the Phase 2 study of cavosonstat as an …

H.C. Wainwright Trims Price Target on TG Therapeutics Inc (TGTX) But Remains Bullish Following GENUINE Study Results

TG Therapeutics Inc (NASDAQ:TGTX) shares crashed almost 17% yesterday on back of the biotech firm’s announcement that it has filed with the FDA …

H.C. Wainwright Weighs in on Biogen Inc (BIIB) Following World Muscle Society Congress

In a research report released today, H.C.

H.C. Wainwright Weighs in on Biogen Inc (BIIB) Following ECTRIMS Conference

At last week’s European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) conference, Biogen Inc (NASDAQ:BIIB) provided “further clarity” on the “unexpected …

H.C. Wainwright Remains Positive on Biogen Inc (BIIB) Following Publication of Phase 1b PRIME Trial

Last week, Biogen Inc (NASDAQ:BIIB) published its Phase 1b PRIME clinical trial coupled with supporting preclinical data in the latest volume of Nature. In …

2Q Snapshot: H.C. Wainwright Weighs In on ACADIA Pharmaceuticals Inc. (ACAD)

In ACADIA Pharmaceuticals Inc.’s (NASDAQ:ACAD) second-quarter report, investors got a first glimpse of Nuplazid’s early launch in Parkinson’s disease psychosis (PDP).

H.C. Wainwright Shines Light on Amarin Corporation plc (ADR) (AMRN) 2Q:16 Update

In a research report issued Friday, H.C.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts